News & Events
News & Events
Biotalk Episode 3: 2023 Q1 Report: Global Trends in Biopharma Transactions
This episode of Biotalk is focused on Locust Walk’s 2023 First Quarter Market Conditions Report, in which we apply the latest data to analyze current activities in the life sciences deal landscape. Each quarter, Locust Walk’s deal team compiles key statistics and...
2023 Q1 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Frist Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
Biotalk Episode 2: A Conversation with Andrew Allen
On this episode of Biotalk, Locust Walk welcomes Andrew Allen, M.D., Ph.D., Co-Founder, President, CEO, and board member of Gritstone Bio to the podcast. Prior to Gritstone, Dr. Allen co-founded Clovis Oncology and served as CMO. He was CMO at Pharmion Corporation and...
RNA Therapeutics Landscape Overview
Locust Walk views RNA therapeutics in 5 key pillars: RNA Translation Inhibition, Protein Expression, RNA-Targeting Small Molecules, RNA Editing, and RNA-Mediated Protein and Transcriptome Regulation.
Biotalk: Expectations for 2023 Biotech Market
Our first Biotalk podcast is focused on Locust Walk’s 2022 year-in-review market conditions, which was released the first day of JPMorgan and rapidly accumulated over 500 downloads. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing...
2022 Year In Review Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2022 Year In Review Report applies the latest data to analyze current activities in the life sciences deal landscape.